Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
since the have a 100 million in cash , would it be a good idea to repurchase shares at this low price in order for little or no dilution when it comes do ?
looks like we have another year, any thoughts on this
Convertible Senior Notes
In December 2014, we issued $143.8 million of our Convertible Senior Notes due 2019 (the “Notes”) in a registered public offering. The Notes pay 3.0% interest semi-annually in arrears starting on June 1, 2015 and are due December 1, 2019. The initial conversion price was $69.48 per share. Simultaneous with the issuance of the Notes, we entered into “bond hedge” (or purchased call) and “warrant” (or written call) transactions with an affiliate of one of the offering underwriters in order to synthetically raise the initial conversion price of the Notes to $96.21 per share and reduce the potential common stock dilution that may arise from the conversion of the Notes.
The Notes are convertible at the option of the holder under certain circumstances and upon conversion we may elect to settle such conversion in shares of our common stock, cash, or a combination thereof. As a result of our cash conversion option, we separately accounted for the value of the embedded conversion option as a debt discount (with an offset to Additional Paid in Capital (“APIC”)) of $33.6 million. Deferred financing costs are recorded as a reduction of long-term debt in the consolidated balance sheets and are being amortized as additional non-cash interest expense on a straight-line basis over the term of the debt, since this method was not significantly different from the effective interest method.
just a fyi , if i remember right in the Canaccord presentation they said they were looking to acquire injectable capability
would like to see a buy back , they have a 100 million are they going to use the cash to retire the senior convertible notes with out any dilution, any thoughts ..... jtfm what do you think
fyi
Yescarta sales were 75 million last quarter up from 68 million
i agree, this weekend im in indianapolis with my oldest son watching the colts play the bills, last year i want to the iron bowl with my youngest son to watch auburn beat bama , ill never forget these memories
contract pharma convention
4:15-5:30 Networking and Cocktail Reception Sponsored by WellSpring
http://conference.contractpharma.com/agenda/
canaccord presentation
http://wsw.com/webcast/canaccord30/anip/
yes before the opening
my question for art , the company has 76 pipeline products .... what would be the time line for getting those to market
from the conference call , deal envy ?
"And then second follow-up question just on the recent transaction announcement. I guess speaking with some folks in industry, including some who were looking at or interested in that package of assets that you acquired through FTC divesture process, a lot of deal envy out there"
noticed in the career section of the website...
http://www.anipharmaceuticals.com/careers_positions.php
hiring for quality assurance,in the past is has been mostly quality control
q/a is for process, q/c is for product, is this to bring more products in the pipeline to market quicker ?
time for a forward stock split ?
yup , tired of this hard knock life
wow, they need to put a dent in to that
i have lost count of the pipline , is still around 70
perhaps corticotropin is proceeding as such they can start to put emphasis on their other drugs in the pipeline
new corporate presentation
https://www.sec.gov/Archives/edgar/data/1023024/000114420418013191/tv487940_ex99-1.htm
is it significant that this conference is for institutional investors
shouldnt we be getting a new corporate presentation for Wednesdays conference
post today on ani's facebook page, they need full, part time , temp production operators
https://www.facebook.com/pg/ANI-Pharmaceuticals-Inc-111453172204421/jobs/137761320186962/?source=post_homepage_stream
does your valuation include the Corticotropin commercialization
i could try to make a closed group facebook page for ani investors if anyone is interested
would mind that , as long as we get a proper valuation on our shares, if teva can right the ship that would be a good investment in itself
also i cant see them taking on more debt
wouldnt worry about it , you will be glad you did
could this rumor be the fruition of bringing libigel to the market where the partner company takes a stake in anip ?
looks like there is a new corporate presentation
http://www.anipharmaceuticals.com/presentations/ANI%20Corporate%20Presentation%20August%202017.pdf
yet another motley fool article
https://www.fool.com/investing/2017/06/12/4-top-small-cap-stocks-to-buy-in-june.aspx?yptr=yahoo
ani info for Inderal
https://www.inderalxl.com/
from the motley fool in case you haven't seen it
https://www.fool.com/investing/2017/05/11/4-of-the-cheapest-biotech-stocks-in-the-world.aspx